AstraZeneca Pharma India Q4 profit falls 23% amid rising costs
AstraZeneca Pharma India saw its fourth-quarter profit drop by 23%, landing at ₹44.8 crore compared to last year's ₹58.2 crore, even though revenue jumped 20.4% to ₹578.6 crore thanks to strong sales in key therapy areas.
Operating costs squeezed profits further, with EBITDA down nearly 30% and margins shrinking from 17.9% to just 10.5%.
AstraZeneca FY26 revenue ₹2,275.6cr 11 approvals
AstraZeneca scored 11 new regulatory approvals for medicines in fiscal 2026 and grew its overall yearly revenue to ₹2,275.6 crore across oncology, biopharmaceuticals, and rare disease segments.
The board also proposed a ₹36 dividend per share and plans to reappoint Shilpa Divekar Nirula as nonexecutive independent director for five more years (pending shareholder nod).
Before the earnings announcement, shares rose by 2.56%, closing at ₹9,025 on the NSE, so investors seem optimistic about what's next.